BALTIMORE, MD--(Marketwired - May 10, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that according to a recent article in the highly regarded bioscience publication BioSpectrum Asia, Nuvilex Inc. (
The Firm has established a research cell bank in concert with a leading contract research organization in Europe. This cell bank will be used for the production of the Company's live cell encapsulation offering, which has demonstrated significant ability to activate the cancer pro-drug ifosfamide in close proximity to the pancreatic cancer itself, thus resulting in a high degree of antitumor efficacy with a low toxicity profile for the anticancer drug, in Phase II clinical trials.
Given that a Phase III pancreatic cancer trial or trials to treat other forms of cancer would require a large number of cells due to number of study subjects, Nuvilex (
The remarkable performance of the Company's encapsulated cell technology platform for pancreatic cancer has been cited in a number of medical journals and publications including the highly regarded Lancet and Cancer Therapy. Plus, data from the aforementioned pancreatic trial studies was recently featured in a review of promising cancer therapies by leading international scientists from the International Society for Cell and Gene Therapy.
Validation from these well-regarded third-party sources and the launch of the cell bank indicate that Nuvilex (
To view a summary of Nuvilex reports or download the reports in their entirety, please visit www.goldmanresearch.com
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (